Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kronos Bio, Inc. - Common Stock (NQ:KRON)

0.7052 -0.0092 (-1.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kronos Bio, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
From Kronos Bio, Inc.
Via GlobeNewswire
KRON Stock Earnings: Kronos Bio Misses EPS, Beats Revenue for Q1 2024
KRON stock results show that Kronos Bio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Kronos Bio Reports First-Quarter 2024 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Recap: Kronos Bio Q4 Earnings
Via Benzinga
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023
KRON stock results show that Kronos Bio beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
Company eliminates three executive officer roles and appoints new Executive Leadership team 
From Kronos Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study
Kronos Bio Inc (NASDAQ: KRON) says that after the review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory... 
Via Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates... 
Via Benzinga
Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket
Shares of Applied UV, Inc. (NASDAQ: AUVI) shares jumped in pre-market trading after the company reported third-quarter results. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope 
From Kronos Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.